

REVENIO

Revenio Group Corporation: Transfer of the Company's own shares

Revenio Group Corporation | Stock Exchange Release | May 07, 2024 at 16:30:00 EEST

Revenio Group Corporation has on May 7, 2024, transferred 3,200 Company's treasury shares (REG1V) to the members of the Board of Directors as part of the remuneration of the Board.

Revenio Group Corporation's AGM decided on April 4, 2024 that approximately 40 percent of the Board members' annual remuneration (gross) will be settled in the form of the company's shares held in its treasury, however not exceeding a maximum of 3,200 shares in total, while approximately 60 percent will consist of a monetary payment. Tax will be deducted from the monetary payment, calculated on the amount of the entire annual remuneration.

The AGM decided that the Chairman of the Board be entitled to an annual emolument of EUR 60,000, the possible deputy chair of the Board of Directors be entitled to an annual emolument of EUR 45,000, the Board Members be entitled to an annual emolument of EUR 30,000, the chair of the Audit Committee be entitled to an annual emolument of EUR 20,000, the chair of the Nomination and Remuneration Committee be entitled to an annual emolument of EUR 10,000, and the members of the Board Committees be entitled to an annual emolument of EUR 5,000. The share payment will be valued using the weighted average value of the share on the day following the release of the Interim Report January 1- March 31, 2024.

As a result of these transfers, the share-based board member fees have been completely settled for the year 2024. Revenio Group Corporation now holds a total of 85,142 of its treasury shares.

For further information, please contact

Robin Pulkkinen, CFO, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

Distribution

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

www.reveniogroup.fi/en

Revenio Group in brief

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.

REVENIO

In 2023, the Group's net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation: Transfer of the Company's own shares](#)